1. Home
  2. RLAY vs EFC Comparison

RLAY vs EFC Comparison

Compare RLAY & EFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Relay Therapeutics Inc.

RLAY

Relay Therapeutics Inc.

HOLD

Current Price

$8.66

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

EFC

Ellington Financial Inc.

HOLD

Current Price

$13.96

Market Cap

1.5B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
RLAY
EFC
Founded
2015
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.5B
IPO Year
2020
2010

Fundamental Metrics

Financial Performance
Metric
RLAY
EFC
Price
$8.66
$13.96
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
7
Target Price
$16.00
$14.46
AVG Volume (30 Days)
2.3M
1.7M
Earning Date
11-06-2025
11-05-2025
Dividend Yield
N/A
11.27%
EPS Growth
N/A
1.22
EPS
N/A
1.33
Revenue
$8,355,000.00
$329,815,000.00
Revenue This Year
$20.47
N/A
Revenue Next Year
N/A
$8.81
P/E Ratio
N/A
$10.39
Revenue Growth
N/A
13.84
52 Week Low
$1.78
$11.12
52 Week High
$9.04
$14.40

Technical Indicators

Market Signals
Indicator
RLAY
EFC
Relative Strength Index (RSI) 66.27 60.57
Support Level $7.95 $13.54
Resistance Level $9.04 $13.79
Average True Range (ATR) 0.50 0.15
MACD 0.03 0.02
Stochastic Oscillator 75.93 92.55

Price Performance

Historical Comparison
RLAY
EFC

About RLAY Relay Therapeutics Inc.

Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).

About EFC Ellington Financial Inc.

Ellington Financial Inc is a specialty finance company. Its primary investment objective is to generate attractive, risk-adjusted total returns for its shareholders by making investments. The company has two reportable segments; The Investment Portfolio Segment is focused on investing in a diverse array of financial assets, including residential and commercial mortgage loans, residential mortgage-backed securities, non-mortgage- and mortgage-related derivatives, debt and equity investments in loan origination companies, and other strategic investments, and The Longbridge Segment is focused on the origination and servicing of reverse mortgage loans. it acquires reverse mortgage loans both through its origination activities and through secondary market purchases.

Share on Social Networks: